[go: up one dir, main page]

WO2008136511A1 - Therapeutic agent for diabetic neuropathy - Google Patents

Therapeutic agent for diabetic neuropathy Download PDF

Info

Publication number
WO2008136511A1
WO2008136511A1 PCT/JP2008/058420 JP2008058420W WO2008136511A1 WO 2008136511 A1 WO2008136511 A1 WO 2008136511A1 JP 2008058420 W JP2008058420 W JP 2008058420W WO 2008136511 A1 WO2008136511 A1 WO 2008136511A1
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic neuropathy
therapeutic agent
disclosed
agonist
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/058420
Other languages
French (fr)
Japanese (ja)
Inventor
Masamitsu Nakazato
Itaru Kyoraku
Kazutaka Shiomi
Yujiro Hayashi
Kenji Kangawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miyazaki NUC
National Cerebral and Cardiovascular Center
Asubio Pharma Co Ltd
Original Assignee
University of Miyazaki NUC
National Cerebral and Cardiovascular Center
Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miyazaki NUC, National Cerebral and Cardiovascular Center, Asubio Pharma Co Ltd filed Critical University of Miyazaki NUC
Publication of WO2008136511A1 publication Critical patent/WO2008136511A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed is a therapeutic agent for diabetic neuropathy, which comprises an agonist of a growth hormone secretion stimulation factor receptor or a pharmaceutically acceptable salt thereof as an active ingredient. Also disclosed is method for treating diabetic neuropathy, which comprises administering the substance to an individual.
PCT/JP2008/058420 2007-05-07 2008-05-02 Therapeutic agent for diabetic neuropathy Ceased WO2008136511A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-122897 2007-05-07
JP2007122897 2007-05-07

Publications (1)

Publication Number Publication Date
WO2008136511A1 true WO2008136511A1 (en) 2008-11-13

Family

ID=39943615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058420 Ceased WO2008136511A1 (en) 2007-05-07 2008-05-02 Therapeutic agent for diabetic neuropathy

Country Status (1)

Country Link
WO (1) WO2008136511A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087102A1 (en) * 2010-01-15 2011-07-21 国立大学法人宮崎大学 Therapeutic agent for promoting recovery of animal under medical treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041901A2 (en) * 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Therapeutics using somatostatin agonists
WO2006033341A1 (en) * 2004-09-22 2006-03-30 Kureha Corporation Therapeutic or preventive agent for diabetic neuropathy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041901A2 (en) * 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Therapeutics using somatostatin agonists
WO2006033341A1 (en) * 2004-09-22 2006-03-30 Kureha Corporation Therapeutic or preventive agent for diabetic neuropathy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IRAKO T. ET AL.: "Ghrelin wa Shinseiji Tonyobyo Model Rat no Tonyobyo Hassho o Soshi suru", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 49, no. SUPPL. 1, 25 April 2006 (2006-04-25), pages S211 *
NAKAZATO N.: "Nanchisei Neuropathy no Byotai ni Motozuku Shinki Chiryoho no Kaihatsu Tonyobyosei Neuropathy ni Taisuru Shinki Peptide Ghrelin o Mochiita Aratana Chiryoho no Kaihatsu", NANCHISEI NEUROPATHY NO BYOTAI NI MOTOZUKU SHINKI CHIRYOHO NO KAIHATSU HEISEI 16-18 NENDO SOKATSU KENKYU HOKOKUSHO, 2006, pages 24 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087102A1 (en) * 2010-01-15 2011-07-21 国立大学法人宮崎大学 Therapeutic agent for promoting recovery of animal under medical treatment
US9078868B2 (en) 2010-01-15 2015-07-14 University Of Miyazaki Therapeutic agent for accelerating recovery of animal under medical treatment

Similar Documents

Publication Publication Date Title
WO2010122980A8 (en) NOVEL THYROID HORMONE β RECEPTOR AGONIST
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2008096775A1 (en) Therapeutic agent for pain disease
MX2010013766A (en) Rasagiline for parkinson's disease modification.
NO20073959L (en) Quinazoline derivative, method of preparation and use thereof for inhibiting cancer cell growth
NO20074628L (en) Controlled release octreotide formulations
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
AR047993A1 (en) PHARMACEUTICAL COMPOSITION THAT PIMOBENDAN INCLUDES
BR112015010314A8 (en) compound or pharmaceutically acceptable salts or isomers thereof, pharmaceutical composition, insulin secretagogue or hypoglycemic agent, gpr40 receptor agonist, and, method of treating diseases or disorders
WO2005115361A3 (en) Androgen receptor modulators and method of treating disease using the same
WO2008027854A3 (en) Pharmaceutical compositions comprising hgh for oral delivery
WO2006086488A3 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2010107807A3 (en) Compounds for treating inflammation and pain
WO2010053861A3 (en) Biologically active amides
WO2010138770A3 (en) Methods for administration and formulations for the treatment of regional adipose tissue
WO2008144269A3 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
EP2316420A8 (en) Method to reduce pain
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
WO2008100448A3 (en) Method of treating cell proliferative disorders using growth hormone secretagogues
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2007145863A3 (en) Sustained release formulation of naltrexone
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
WO2006108176A3 (en) Wound healing composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08752325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP